| BSE: 532321 | Sector: Health care |
| NSE: CADILAHC | ISIN Code: INE010B01027 |
| BSE 00:00 | 20 Jun | 410.65 |
2.75 (0.67%) |
OPEN
410.50 |
HIGH
413.75 |
LOW
403.50 |
| NSE 00:00 | 20 Jun | 411.80 |
2.85 (0.70%) |
OPEN
412.85 |
HIGH
413.45 |
LOW
403.25 |
| OPEN | 410.50 |
| PREVIOUS CLOSE | 407.90 |
| VOLUME | 79809 |
| 52-Week high | 554.20 |
| 52-Week low | 341.65 |
| P/E | 38.52 |
| Mkt Cap.(Rs cr) | 42,038 |
| Buy Price | 0.00 |
| Buy Qty | 0.00 |
| Sell Price | 0.00 |
| Sell Qty | 0.00 |
3.16 am | 12 Jun 2018 | Business Standard
In May, price growth for drugs was in negative territory at (-)1 per cent
10.22 am | 8 Jun 2018 | Business Standard
Sun Pharma, Cadila Healthcare, Dr Reddy's Laboratories, Cipla, Glenmark Pharma and Lupin from the Nifty Pharma index were up in the range of 2% to 3% ...
10.41 pm | 6 Jun 2018 | Business Standard
The stock, which has been trending down due to weak sentiment towards the pharma sector, could provide a good opportunity for investors at current val...
1.18 am | 26 May 2018 | Business Standard
Strong Q4, healthy forecast could result in more upside for stock
11.15 pm | 25 May 2018 | Business Standard
Standalone profit down 48% to Rs 24.3 bn; company gets board nod for fund raising proposals
9.37 pm | 31 Mar 2018 | Business Standard
Teva launched the generic version of Irish firm Shire's Lialda in the US earlier this week
2.02 am | 31 Mar 2018 | Business Standard
While analysts have cut their forward net profit estimates to factor in the challenges, the correction in stock prices, according to them, is exaggera...
10.06 am | 26 Mar 2018 | Business Standard
The stock was trading 4% higher at Rs 385 as compared to 0.01% rise in the S&P BSE Sensex at 09:45 am.
4.58 pm | 28 Feb 2018 | Press Trust of India
The injection will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad
11.53 pm | 9 Feb 2018 | Business Standard
Company has already received highest number of USFDA approvals since April 2017 and aims to launch 75% of these
5.34 pm | 8 Feb 2018 | Business Standard
Ahmedabad-based Cadila Healthcare has posted a 68 per cent year on year (YoY) jump in net profit for the third quarter of the current fiscal on the ba...
3.10 pm | 8 Feb 2018 | Business Standard
At 02:59 PM; Nifty Pharma index, the largest gainer among sectoral indices, was up 3.6% as compared to 1.01% rise in the benchmark Nifty 50 index
9.13 pm | 24 Jan 2018 | Business Standard
Analysts expect the two segments to contribute 25% of domestic revenue in 2 years; vaccines contribute less than 1% of revenues at present, while bios...
1.14 am | 11 Jan 2018 | Business Standard
Indian pharma firms including their subsidiaries have received around 304 abbreviated new drug application approvals from the USFDA in 2017
11.54 pm | 2 Jan 2018 | Business Standard
As the 2017-18 financial year enters the final quarter, a look at formulation approvals by the US Food and Drug Administration (FDA) in the year till ...
3.02 pm | 29 Dec 2017 | Press Trust of India
Zydus Pharmaceuticals Inc is a wholly-owned subsidiary of Cadila Healthcare Ltd
3.35 pm | 21 Dec 2017 | Business Standard
Zydus Healthcare is a wholly owned subsidiary of Cadila Healthcare
